2026 CSCCP-ASCCP Colposcopy Training Course–Wuhan Station Concludes, Promoting More Precise and Non-Invasive Management of Cervical Lesions

Advancing Precision Diagnosis and TreatmentPhotodynamic Therapy Introduced for the First Time into Colposcopy Faculty Training in ChinaWUHAN, China, Oct. 23, 2026 /PRNewswire/ -- The 2026 CSCCP-ASCCP Colposcopy Training Course, held in Wuhan from October 21 to 23, concluded…

Continue Reading2026 CSCCP-ASCCP Colposcopy Training Course–Wuhan Station Concludes, Promoting More Precise and Non-Invasive Management of Cervical Lesions

Volvo Cars Q3 2026: taking decisive action to navigate a very tough environment

GOTHENBURG, Sweden, Oct. 23, 2026 /PRNewswire/ -- Volvo Cars today reports an operating income, excluding joint ventures & associates and items affecting comparability, of SEK -3.7 billion and a corresponding EBIT margin of -5.6 per cent for the third…

Continue ReadingVolvo Cars Q3 2026: taking decisive action to navigate a very tough environment

ANCEL Survey: 95.2% of Super Starter Users Report Improved Vehicle Starting Performance

MARIETTA, Ga., Oct. 22, 2026 /PRNewswire/ -- Starting difficulties aren't limited to long-parked vehicles; daily-driven cars frequently struggle due to short trips, parked battery drain, or cold weather. To explore performance, ANCEL surveyed 114 Super Starter users through…

Continue ReadingANCEL Survey: 95.2% of Super Starter Users Report Improved Vehicle Starting Performance

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

  • Post author:
  • Post category:Sales & Growth

SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ --  ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate in…

Continue ReadingImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026